Three conferences shaped this issue of Discovery Insider, and they tell one story.
At ELRIG Drug Discovery USA, degraders and molecular glues brought once undruggable targets within reach. At BIO International, the focus shifted to dealmaking and what keeps a program funded. At AAIC, tau-targeting approaches gained ground alongside amyloid.
Together, the coverage traces how discovery science moves from the bench to the pipeline, and what that means for drug developers at every stage.
